Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd
The upcoming Phase III trial with Diamyd in new-onset type 1 diabetes will be based on the first precision medicine approach in the field. The trial is designed to confirm the effect and safety of Diamyd in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.
The Phase III trial is designed to enroll approximately 330 individuals aged 12 to 28, recently diagnosed with type 1 diabetes, who carry the HLA DR3-DQ2 haplotype. This patient population is based on clinical efficacy and safety results from the Phase IIa and Phase IIb trials DIAGNODE-1 and DIAGNODE-2, as well as the large-scale meta-analysis encompassing data from more than 600 individuals from previous Phase II and Phase III trials using Diamyd
David Plouffe, an architect of President Obama's winning campaign and specialist in the intersection of grassroots and tech, joins Precision — and co-founders Stephanie Cutter and Teddy Goff — as "of counsel."What they're saying: Cutter pointed to "David’s experience in creating and driving data-driven strategies and managing integrated campaigns."Get market news worthy of your time with Axios Markets. Subscribe for free.Goff said: "David is a legend to just about every young person who worked on the Obama campaigns."Plouffe said Precision wowed with "innovative work for the Democratic National Convention and the inaugural events."The big picture: Plouffe was a top Uber executive, leading global policy and communications.He helped Mark Zuckerberg and Priscilla Chan launch the Chan Zuckerberg Initiative, where he remains an adviser on the criminal justice and immigration portfolios.Plouffe is on the boards of Oscar H
Royal Philips: Philips spotlights new integrated informatics and system solutions to drive workflow optimization and advance precision diagnosis at ECR 2021
Expanded Philips Radiology Workflow Suite features new, AI-enabled solutions to streamline workflows across the entire imaging enterprise
Solutions integrate and automate workflow to help improve efficiency and clinical confidence to enable earlier and more definitive diagnosis
Philips portfolio of award-winning diagnostic systems and interventional solutions will be featured in a unique virtual ECR experience
Amsterdam, the Netherlands -
Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its participation in the European Congress of Radiology (ECR) virtual event, March 3-7, 2021, where the company will feature new and enhanced diagnostic and interventional solutions that further expand its Radiology Workflow Suite, connecting data, technology and people across the imaging enterprise
QF and Al Jazeera make documentary on precision medicine
27 Feb 2021 - 10:34
A screenshot from the documentary, The Book of Life–Precision Medicine.
The Peninsula
Doha: Qatar Foundation (QF) has teamed up with Al Jazeera to produce a documentary on precision medicine which was aired on Thursday on Al Jazeera Arabic. The documentary titled The Book of Life–Precision Medicine showcases QF’s efforts and investments in this area, which is said to be the future of healthcare.
Precision medicine is an approach for disease treatment that factors in individual differences in genes, environment, and lifestyle for each person. Why do some people react differently to certain drugs, or why are some people becoming severely ill with SARS-CoV-2 whereas others are showing no symptoms – these are questions precision medicine seeks to answer, thereby offering accurate diagnosis and effective treatment.